ENDEAVOR III: A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
Study of:
Medtronic Endeavor Drug (ABT-578) Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System
The purpose of this study is to establish the safety and efficacy of the Endeavor stent coated with the drug ABT 578. ABT 578 can prevent tissue growth on the inside of the stent by affecting cell growth. In this study a comparison will be made between the Endeavor stent and the already approved Cypher stent coated with the drug rapamycin for treatment of blockages in native coronary arteries. All patients will return for a follow-up angiogram at eight months to verify if any re-narrowing has occurred.
- M. Nicholas Burke, MD
- Ivan J. Chavez, MD, FACC
- Timothy D. Henry, MD, FACC
- John R. Lesser, MD, FACC
- Daniel Lips, MD, FACC
- James D. Madison, MD, FACC
- Wesley R. Pedersen, MD, FACC
- Anil K. Poulose, MD, FACC
- Jay H. Traverse, MD, FACC, FAHA
- Yale Wang, MD, FACC, FSCAI
For more information about this study or the Interventional Cardiology Research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124. |